ATE384075T1 - Markierte glutamin- und lysinanaloge - Google Patents

Markierte glutamin- und lysinanaloge

Info

Publication number
ATE384075T1
ATE384075T1 AT99922325T AT99922325T ATE384075T1 AT E384075 T1 ATE384075 T1 AT E384075T1 AT 99922325 T AT99922325 T AT 99922325T AT 99922325 T AT99922325 T AT 99922325T AT E384075 T1 ATE384075 T1 AT E384075T1
Authority
AT
Austria
Prior art keywords
glutamine
lysine analogues
lysine
labeled glutamine
peptidases
Prior art date
Application number
AT99922325T
Other languages
English (en)
Inventor
Anthony Eamon Storey
Marivi Mendizabal
Susan Champion
Alex Gibson
Benedicte Guilbert
Ian Andrew Wilson
Peter Knox
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of ATE384075T1 publication Critical patent/ATE384075T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99922325T 1998-05-15 1999-05-14 Markierte glutamin- und lysinanaloge ATE384075T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98303872 1998-05-15

Publications (1)

Publication Number Publication Date
ATE384075T1 true ATE384075T1 (de) 2008-02-15

Family

ID=8234827

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922325T ATE384075T1 (de) 1998-05-15 1999-05-14 Markierte glutamin- und lysinanaloge

Country Status (17)

Country Link
US (2) US7049289B1 (de)
EP (1) EP1077998B1 (de)
JP (2) JP4199420B2 (de)
KR (1) KR100660509B1 (de)
CN (2) CN101407543A (de)
AT (1) ATE384075T1 (de)
AU (1) AU762736B2 (de)
BR (1) BR9910468A (de)
CA (1) CA2332277A1 (de)
DE (1) DE69937996T2 (de)
ES (1) ES2299245T3 (de)
HU (1) HUP0102154A3 (de)
IL (1) IL139385A (de)
NO (1) NO20005751L (de)
RU (1) RU2205186C2 (de)
WO (1) WO1999060018A1 (de)
ZA (1) ZA200006313B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433657A1 (en) * 2001-01-05 2002-07-11 Duke University Contrast enhancement agent for magnetic resonance imaging
CN1622830A (zh) * 2001-07-10 2005-06-01 安盛药业有限公司 肽基化合物
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
GB0224799D0 (en) * 2002-10-25 2002-12-04 Amersham Plc Improved complex compositions
WO2004106939A2 (en) * 2003-06-03 2004-12-09 Paul Scherrer Institut Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides
GB0515974D0 (en) * 2005-08-03 2005-09-07 Ge Healthcare Ltd Compounds and imaging methods
RU2428415C2 (ru) 2005-11-29 2011-09-10 Нихон Меди-Физикс Ко., Лтд. Соединение-предшественник органического соединения, меченного радиоактивным галогеном
WO2008060368A2 (en) * 2006-10-02 2008-05-22 Duke University Transglutaminase-binding peptides and methods of use
US20130195756A1 (en) 2012-01-31 2013-08-01 General Electric Company 99mTc IMAGING AGENTS AND METHODS OF USE
WO2015017815A1 (en) 2013-08-01 2015-02-05 Rochester Institute Of Technology Modular imaging agents containing amino acids and peptides
GB201610176D0 (en) * 2016-06-10 2016-07-27 Edinburgh Molecular Imaging Ltd Imaging agents and methods of use
CN110121563A (zh) * 2016-11-09 2019-08-13 奇根科学有限责任公司 在边合成边测序中作为成像试剂的光保护混合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041023A (en) * 1976-04-14 1977-08-09 Hoffmann-La Roche Inc. Labelled peptides
JPS59186947A (ja) * 1983-03-09 1984-10-23 Kowa Co 新規ペプチド
WO1989000051A1 (en) * 1987-07-07 1989-01-12 Cytrx Biopool Ltd. Fibrin-binding compound and method
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
WO1993012819A1 (en) * 1992-01-03 1993-07-08 Rhomed Incorporated Protein- and peptide-metal ion pharmaceutical applications
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
JP2001512502A (ja) * 1997-01-21 2001-08-21 ナイコメッド・アマーシャム・ピーエルシー 標識した因子Ｘ▲ＩＩＩ▼ａ基体

Also Published As

Publication number Publication date
IL139385A (en) 2005-09-25
NO20005751L (no) 2001-01-08
WO1999060018A1 (en) 1999-11-25
JP4199420B2 (ja) 2008-12-17
DE69937996T2 (de) 2009-01-02
CN1309661A (zh) 2001-08-22
NO20005751D0 (no) 2000-11-14
HUP0102154A2 (hu) 2001-09-28
KR20010043608A (ko) 2001-05-25
JP2006137751A (ja) 2006-06-01
ZA200006313B (en) 2002-07-17
AU762736B2 (en) 2003-07-03
AU3942899A (en) 1999-12-06
ES2299245T3 (es) 2008-05-16
US20060292075A1 (en) 2006-12-28
EP1077998B1 (de) 2008-01-16
DE69937996D1 (de) 2008-03-06
RU2205186C2 (ru) 2003-05-27
HUP0102154A3 (en) 2009-01-28
BR9910468A (pt) 2001-01-09
KR100660509B1 (ko) 2006-12-22
EP1077998A1 (de) 2001-02-28
CA2332277A1 (en) 1999-11-25
JP2002515510A (ja) 2002-05-28
CN101407543A (zh) 2009-04-15
IL139385A0 (en) 2001-11-25
US7049289B1 (en) 2006-05-23

Similar Documents

Publication Publication Date Title
DE69937996D1 (de) Markierte glutamin- und lysinanaloge
AU659550B2 (en) Dual action inhibitors
SE8502573D0 (sv) Fluorescent lanthanide chelates useful as labels of physiologically active materials
FI955851L (fi) Synergistisesti stabiloituja nestemäisiä entsymaattisia koostumuksia
DE69637957D1 (de) Zusammensetzung für düngemitteladditivconzentrat
CO4650176A1 (es) Metodo para la fabricacion de paneles laterales para articulos desechables
TR28128A (tr) Deterjan bilesimlerinde kir salma maddeleri olarak kullanima müsait sülfone poli-etoksi/propoksi uc-baslikli ester oligomerleri.
DE69431209D1 (de) Transdermale prostaglandin-zusammensetzung
ATE280241T1 (de) Chemilumineszierende zusammensetzungen und entsprechende verfahren
DE69417749D1 (de) Nichtklebende zusammensetzung
FI941832A7 (fi) Menetelmiä NMR:llä havaittavien ksenobioottisten yhdisteiden in vivo määrittämiseksi
FI921279A7 (fi) Amino-b-lyaasientsyymin inhibiittorit deodorantteina
BR9908412A (pt) Composição enzimática estabilizada e método para sua preparação
ES2093819T3 (es) Procedimiento y composicion para determinar la susceptibilidad antimicrobiana de la mayoria de los organismos gram positivos clinicamente significativos.
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
GB2324091A (en) Metalloproteinase inhibitors
DE69809944D1 (de) Fettsäuren als eine nährungsergänzung
BG100248A (bg) Инхибитори на скваленсинтетаза
PT1211250E (pt) Derivados de taxano em c10 e composicoes farmaceuticas
DE60014960D1 (de) Alizarin-derivate als neue chromogene substrate
BR0114884A (pt) Compostos calcilìticos
DE59808546D1 (de) Verwendung von fettsäureniedrigalkylestern in abbeizmitteln
ATE261124T1 (de) Biotin-peg-substrat für einen lipase-assay
FI19992177A7 (fi) Seriiniproteaasi- ja paikallisesti käytettävä retinoidikoostumuksia
ES2154043T3 (es) Material de obturacion y adhesivo de poliuretano de dos componentes.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties